IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Appl.:

Jonathan W. Nyce

: Art Unit:

1635

Serial No .:

09/093,972

: Examiner:

Dr. Epps

PATENT

Filed:

June 9, 1998

:Appl. Ref. No.: EPI-00672

For:

COMPOSITION, FORMULATIONS & METHOD FOR PREVENTION & TREATMENT OF DISEASES AND CONDITIONS ASSOCIATED WITH BRONCHOCONSTRICTION, ALLERGY(IES) & INFLAMMATION

AMENDMENT

Assistant Commissioner for Patents Washington, D.C. 20231

Sir/Madam:

Responsive to the Office Action of November 7, 2000, please amend the above Identified patent application as follows.

IN THE SPECIFICATION

Please amend the specification as follows.

Page 9, line 6 from last, change "\$, human" into $-\beta$, human --.

Page 10, line 6. change "", "at the end of the line into $-\alpha$ -...

Page 44, in the paragraph added, lines 4-5, delete "colfoceryl-cetyl alcoholtyloxapol or colfosceril palmitate, cetyl alcohol,"; and

line 6, delete "neutral lipids".

445.00 CH

Page 56, line 19, change ", "subunit" into --, β subunit--.

Page 57, line 20, change "factor": "into – factor β : --.

IN THE CLAIMS

Please delete claims 132, 142, 145, 147, 149-150, 157, 160, 174, 177, 182, 194

and 199, and amend the remaining claims as follows:

A pharmaceutical composition, comprising

Sale Ref: 00000003 DA#: 501728 090

108. (Amended) 09093972

a carrier;

01 FC:217

a nucleic acid [which] in the form of an aerosol that comprises [at least] one or